# Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

> **NCT05919238** · PHASE1 · RECRUITING · sponsor: **Impact Biotech Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Unresectable Pancreatic Adenocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Padeliporfin Vascular Targeted Photodynamic (VTP) therapy

## Key facts

- **NCT ID:** NCT05919238
- **Lead sponsor:** Impact Biotech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05919238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05919238, "Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05919238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*